Meta Information

ID:pitavastatin

Name:Pitavastatin

Schema Version:1.5

Alternate Names

• Livalo
• Zypitamag

Intervention Type

therapeutic_agent

Expected Cost Mean

Low Cost:

15

High Cost:

60

Cost Type:

monthly

Description:

Generic prescription cost; often covered by insurance, sometimes requiring prior authorization.

Summary

Pitavastatin is a statin medication that lowers LDL cholesterol and ApoB by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. Its primary healthspan relevance is the significant reduction of atherosclerotic cardiovascular disease (ASCVD) risk, a leading cause of age-related mortality. Unlike some other statins, evidence suggests it has a neutral or potentially beneficial effect on glucose metabolism, making it a compelling choice for individuals concerned with insulin resistance.

Purpose

Lowers LDL cholesterol to reduce atherosclerotic cardiovascular disease risk.

Card Summary

A statin that lowers LDL cholesterol to reduce cardiovascular disease risk, with potentially fewer metabolic side effects.

Drug Class

statins

Drugs In Class

Empty Array

Impact

Score:

8.5

Justification:

Dramatically reduces ASCVD risk, a primary driver of age-related mortality and morbidity.

Evidence

Grade:

A

Score:

9.8

Justification:

Extensive, large-scale human RCTs and meta-analyses confirm robust cardiovascular event reduction.

Safety

Score:

4.5

Justification:

Generally well-tolerated but carries risks of myopathy and requires medical supervision.

Flags

• Myalgia (muscle pain) is the most commonly reported side effect.
• Rare but serious risks include rhabdomyolysis (severe muscle breakdown) and liver injury.
• Interacts with cyclosporine, certain fibrates (like gemfibrozil), and some HIV/HCV protease inhibitors.
• Considered to have a lower risk of inducing new-onset diabetes compared to other statins.

Verdict

A top-tier choice for lowering ApoB/LDL-C with a favorable metabolic profile.

Created

2026-04-27T01:01:27.894037Z

Model

Gemini 3.1 Pro (High)

Delivery

Route:

oral

Scope:

• systemic

Indication

Focus:

disease_treatment

Description:

Pitavastatin is a statin medication that lowers LDL cholesterol and ApoB by inhibiting HMG-CoA reductase, a key enzyme in cholesterol synthesis. Its primary healthspan relevance is the significant red...

Typical Protocol

• Typical daily dosage ranges from 1 mg to 4 mg, taken orally, to target specific ApoB or LDL-C levels.